Cargando…

Vector-based genetically modified vaccines: Exploiting Jenner’s legacy

The global vaccine market is diverse while facing a plethora of novel developments. Genetic modification (GM) techniques facilitate the design of ’smarter’ vaccines. For many of the major infectious diseases of humans, like AIDS and malaria, but also for most human neoplastic disorders, still no vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramezanpour, Bahar, Haan, Ingrid, Osterhaus, Ab, Claassen, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115478/
https://www.ncbi.nlm.nih.gov/pubmed/28029542
http://dx.doi.org/10.1016/j.vaccine.2016.06.059
_version_ 1783514106674806784
author Ramezanpour, Bahar
Haan, Ingrid
Osterhaus, Ab
Claassen, Eric
author_facet Ramezanpour, Bahar
Haan, Ingrid
Osterhaus, Ab
Claassen, Eric
author_sort Ramezanpour, Bahar
collection PubMed
description The global vaccine market is diverse while facing a plethora of novel developments. Genetic modification (GM) techniques facilitate the design of ’smarter’ vaccines. For many of the major infectious diseases of humans, like AIDS and malaria, but also for most human neoplastic disorders, still no vaccines are available. It may be speculated that novel GM technologies will significantly contribute to their development. While a promising number of studies is conducted on GM vaccines and GM vaccine technologies, the contribution of GM technology to newly introduced vaccines on the market is disappointingly limited. In this study, the field of vector-based GM vaccines is explored. Data on currently available, actually applied, and newly developed vectors is retrieved from various sources, synthesised and analysed, in order to provide an overview on the use of vector-based technology in the field of GM vaccine development. While still there are only two vector-based vaccines on the human vaccine market, there is ample activity in the fields of patenting, preclinical research, and different stages of clinical research. Results of this study revealed that vector-based vaccines comprise a significant part of all GM vaccines in the pipeline. This study further highlights that poxviruses and adenoviruses are among the most prominent vectors in GM vaccine development. After the approval of the first vectored human vaccine, based on a flavivirus vector, vaccine vector technology, especially based on poxviruses and adenoviruses, holds great promise for future vaccine development. It may lead to cheaper methods for the production of safe vaccines against diseases for which no or less perfect vaccines exist today, thus catering for an unmet medical need. After the introduction of Jenner’s vaccinia virus as the first vaccine more than two centuries ago, which eventually led to the recent eradication of smallpox, this and other viruses may now be the basis for constructing vectors that may help us control other major scourges of mankind.
format Online
Article
Text
id pubmed-7115478
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71154782020-04-02 Vector-based genetically modified vaccines: Exploiting Jenner’s legacy Ramezanpour, Bahar Haan, Ingrid Osterhaus, Ab Claassen, Eric Vaccine Article The global vaccine market is diverse while facing a plethora of novel developments. Genetic modification (GM) techniques facilitate the design of ’smarter’ vaccines. For many of the major infectious diseases of humans, like AIDS and malaria, but also for most human neoplastic disorders, still no vaccines are available. It may be speculated that novel GM technologies will significantly contribute to their development. While a promising number of studies is conducted on GM vaccines and GM vaccine technologies, the contribution of GM technology to newly introduced vaccines on the market is disappointingly limited. In this study, the field of vector-based GM vaccines is explored. Data on currently available, actually applied, and newly developed vectors is retrieved from various sources, synthesised and analysed, in order to provide an overview on the use of vector-based technology in the field of GM vaccine development. While still there are only two vector-based vaccines on the human vaccine market, there is ample activity in the fields of patenting, preclinical research, and different stages of clinical research. Results of this study revealed that vector-based vaccines comprise a significant part of all GM vaccines in the pipeline. This study further highlights that poxviruses and adenoviruses are among the most prominent vectors in GM vaccine development. After the approval of the first vectored human vaccine, based on a flavivirus vector, vaccine vector technology, especially based on poxviruses and adenoviruses, holds great promise for future vaccine development. It may lead to cheaper methods for the production of safe vaccines against diseases for which no or less perfect vaccines exist today, thus catering for an unmet medical need. After the introduction of Jenner’s vaccinia virus as the first vaccine more than two centuries ago, which eventually led to the recent eradication of smallpox, this and other viruses may now be the basis for constructing vectors that may help us control other major scourges of mankind. The Author(s). Published by Elsevier Ltd. 2016-12-07 2016-10-28 /pmc/articles/PMC7115478/ /pubmed/28029542 http://dx.doi.org/10.1016/j.vaccine.2016.06.059 Text en © 2016 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ramezanpour, Bahar
Haan, Ingrid
Osterhaus, Ab
Claassen, Eric
Vector-based genetically modified vaccines: Exploiting Jenner’s legacy
title Vector-based genetically modified vaccines: Exploiting Jenner’s legacy
title_full Vector-based genetically modified vaccines: Exploiting Jenner’s legacy
title_fullStr Vector-based genetically modified vaccines: Exploiting Jenner’s legacy
title_full_unstemmed Vector-based genetically modified vaccines: Exploiting Jenner’s legacy
title_short Vector-based genetically modified vaccines: Exploiting Jenner’s legacy
title_sort vector-based genetically modified vaccines: exploiting jenner’s legacy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115478/
https://www.ncbi.nlm.nih.gov/pubmed/28029542
http://dx.doi.org/10.1016/j.vaccine.2016.06.059
work_keys_str_mv AT ramezanpourbahar vectorbasedgeneticallymodifiedvaccinesexploitingjennerslegacy
AT haaningrid vectorbasedgeneticallymodifiedvaccinesexploitingjennerslegacy
AT osterhausab vectorbasedgeneticallymodifiedvaccinesexploitingjennerslegacy
AT claasseneric vectorbasedgeneticallymodifiedvaccinesexploitingjennerslegacy